Vinzolidine

Vinzolidine

SCHEMBL18660

CC[C@]1(O)C[C@H]2C[N@](CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@]5(OC(=O)N(CCCl)C5=O)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.79
MEN1 O00255 7/20 0.79
KMT2A Q03164 7/20 0.79
TUBB4A P04350 7/20 0.79
TUBB P07437 7/20 0.79
TUBA3C P0DPH7 7/20 0.79
TUBA1B P68363 7/20 0.79
TUBA4A P68366 7/20 0.79
TUBB4B P68371 7/20 0.79
TUBB3 Q13509 7/20 0.79
TUBB2A Q13885 7/20 0.79
TUBB8 Q3ZCM7 7/20 0.79
TUBA3E Q6PEY2 7/20 0.79
TUBA1A Q71U36 7/20 0.79
TUBA1C Q9BQE3 7/20 0.79
TUBB6 Q9BUF5 7/20 0.79
TUBB2B Q9BVA1 7/20 0.79
TUBB1 Q9H4B7 7/20 0.79
CYP3A4 P08684 6/20 0.79
LMNA P02545 6/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vinzolidine SCHEMBL29824738 1.00 MAPT (0.79) MAPTMEN1KMT2ATUBB4ATUBB
Vinzolidine SCHEMBL4849 0.98 MAPT (0.80) MAPTMEN1KMT2ATUBB4ATUBB
Vinzolidine SCHEMBL29358211 0.98 MAPT (0.79) MAPTMEN1KMT2ATUBB4ATUBB
Vinzolidine SCHEMBL10646933 0.96 MAPT (0.75) MAPTMEN1KMT2ATUBB4ATUBB
SCHEMBL14379965 0.89 MAPT (0.88) MAPTMEN1KMT2ATUBB4ATUBB
SCHEMBL14498074 0.89 MAPT (0.88) MAPTMEN1KMT2ATUBB4ATUBB
Vinblastine SCHEMBL17813675 0.89 MAPT (1.00) MAPTMEN1KMT2ATUBB4ATUBB
Vinblastine SCHEMBL153952 0.89 MAPT (1.00) MAPTMEN1KMT2ATUBB4ATUBB
Vinblastine SCHEMBL22022258 0.89 MAPT (1.00) MAPTMEN1KMT2ATUBB4ATUBB
Vinblastine SCHEMBL22450052 0.89 MAPT (1.00) MAPTMEN1KMT2ATUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3759 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4524131-A1 SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH AlonBio Ltd. (IL) 2025-03-19 EP claimed
US-12202803-B2 Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death ALONBIO LTD. (IL) 2025-01-21 US claimed
US-20240002347-A1 SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH ALONBIO LTD. (IL) 2024-01-04 US claimed
EP-2796112-B2 Degradable implantable medical devices ELIXIR MEDICAL CORP (US) 2023-08-09 EP claimed
CN-113491690-B Use of 2-acetylnaphtho [2,3-b ] furan-4, 9-dione for treating cancer 北京强新生物科技有限公司 2023-03-14 CN claimed
EP-3441089-B1 TREATMENT METHODS USING ADENOVIRUS VASCULAR BIOGENICS LTD (IL) 2022-12-14 EP claimed
WO-2022087375-A1 NOVEL HETEROCYCLIC COMPOUNDS SPECTRUM PHARMACEUTICALS, INC. (US) 2022-04-28 WO claimed
WO-2022087371-A1 NOVEL BICYCLIC COMPOUNDS SPECTRUM PHARMACEUTICALS, INC. (US) 2022-04-28 WO claimed
CN-113491690-A Use of 2-acetylnaphtho [2,3-b ] furan-4, 9-dione for treating cancer 北京强新生物科技有限公司 2021-10-12 CN claimed
EP-3191114-B1 OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF UNIV MISSISSIPPI STATE (US) 2021-03-03 EP claimed
WO-2002085400-A1 COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE SUPERGEN, INC. (US) 2002-10-31 WO claimed
WO-2002067681-A1 RESTORE CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION SUPERGEN, INC. (US) 2002-09-06 WO claimed
US-20020114809-A1 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation ASTEX PHARMACEUTICALS, INC. 2002-08-22 US claimed
US-20020111362-A1 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same SUPERGEN, INC. 2002-08-15 US claimed
WO-2001080843-A2 INHIBITION OF ABNORMAL CELL PROLIFERATION WITH CAMPTOTHECIN AND COMBINATIONS INCLUDING THE SAME SUPERGEN, INC. (US) 2001-11-01 WO claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed
EP-0147152-B1 IMPROVEMENTS IN OR RELATING TO NOVEL SALTS OF DIMERIC INDOLE-DIHYDROINDOLE ALKALOIDS ELI LILLY AND COMPANY (US) 1988-06-29 EP claimed
US-4558053-A Naphthalene-1,5-disulfonate salts of dimeric indole-dihydroindole alkaloids ELI LILLY AND COMPANY (US) 1985-12-10 US claimed
EP-0147152-A2 Improvements in or relating to novel salts of dimeric indole-dihydroindole alkaloids ELI LILLY AND COMPANY (US) 1985-07-03 EP claimed